At this moment, specific therapies for the treatment of HSMR syndrome due to pathogenic mutations in CNNM2 have yet to be developed. At this moment, the main advices are:
- Mg2+ supplementation
- Anti-consulvants, in case of persistent refractory epilepsy
- Speech therapy in case of speech/communication delay
- Physiotherapy if motor skills defects are identified